Clinical Trials Browser

OTHER × pegcetacoplan × 90 days × Clear all

NCT04919629 2026-03-23

APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion

Phase 2 Recruiting

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT07214298 2026-02-06

Pegcetacoplan in Combination With Modified FOLFIRINOX for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma

Phase 1/2 Recruiting

Gastrointestinal

Pancreatic Neoplasms